Waning antibody response and cellular immunity 6 months after third dose SARS‐Cov‐2 mRNA BNT162b2 vaccine in kidney transplant recipients.

Author(s):  
Dominique Bertrand ◽  
Veronique Lemée ◽  
Charlotte Laurent ◽  
Mathilde Lemoine ◽  
Mélanie Hanoy ◽  
...  
Author(s):  
Ali AlShaqaq ◽  
Maher AlDemerdash ◽  
Abdulnaser AlAbadi ◽  
Baher Elgadaa ◽  
Najib Musaied ◽  
...  

2006 ◽  
Vol 120 (3) ◽  
pp. 342-348 ◽  
Author(s):  
Monika Lindemann ◽  
Oliver Witzke ◽  
Peter Lütkes ◽  
Melanie Fiedler ◽  
Ernst Kreuzfelder ◽  
...  

Author(s):  
Roman Reindl-Schwaighofer ◽  
Andreas Heinzel ◽  
Manuel Mayrdorfer ◽  
Rhea Jabbour ◽  
Thomas M. Hofbauer ◽  
...  

Author(s):  
Nathalie Chavarot ◽  
Antoine Morel ◽  
Marianne Leruez‐Ville ◽  
Estelle Villain ◽  
Gillian Divard ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
pp. 148
Author(s):  
Lukas Buchwinkler ◽  
Claire Anne Solagna ◽  
Janosch Messner ◽  
Markus Pirklbauer ◽  
Michael Rudnicki ◽  
...  

Most trials on mRNA vaccines against SARS-CoV-2 did not include patients with chronic kidney disease (CKD), hemodialysis (HD) patients, or kidney transplant recipients (KTR). However, those patients have a higher risk for a severe course of COVID-19 disease and mortality. Available literature has demonstrated a reduced efficacy of mRNA vaccines in HD patients and KTR, while data on CKD patients is scarce. Additionally, factors associated with non-response are poorly understood and not well characterized. We assessed antibody (AB) response (n = 582, 160 CKD patients, 206 patients on HD, 216 KTR) after the administration of two doses of a mRNA-vaccine with either BNT162b2 or mRNA-1273. AB measurements were carried out after a median of 91 days after first vaccinations, demonstrating non-response in 12.5% of CKD patients, 12.1% of HD patients, and 50% of KTR. AB titers were significantly higher in CKD patients than in HD patients or KTR. Factors associated with non-response were treated with rituximab in CKD patients, the use of calcineurin inhibitors in HD patients and older age, and the use of BNT162b2, mycophenolic acid, or glucocorticoids and lower hemoglobin levels in KTR. This study contributes to the understanding of the extent and conditions that predispose for non-response in patients with impaired kidney function.


2021 ◽  
Vol 8 (1) ◽  
pp. e1257
Author(s):  
Stephanie G. Yi ◽  
Linda W. Moore ◽  
Todd Eagar ◽  
Edward A. Graviss ◽  
Duc T. Nguyen ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Anila Duni ◽  
Georgios S. Markopoulos ◽  
Ioannis Mallioras ◽  
Haralampos Pappas ◽  
Efthymios Pappas ◽  
...  

BackgroundThe humoral and cellular immune responses to SARS-COV-2 vaccination remain to be elucidated in hemodialysis (HD) patients and kidney transplant recipients (KTRs), considering their baseline immunosuppressed status. The aim of our study was to assess the associations of vaccine-induced antibody responses with circulating lymphocytes sub-populations and their respective patterns of alterations in maintenance HD patients and KTRs.Materials and MethodsWe included 34 HD patients and 54 KTRs who received two doses of the mRNA-vaccine BNT162b2. Lymphocyte subpopulations were analyzed by flow cytometry before vaccination (T0), before the second vaccine dose (T1) and 2 weeks after the second dose (T2). The anti-SARS-CoV2 antibody response was assessed at T1 and at T2.Results31 HD patients (91.8%) and 16 KTRs (29.6%) became seropositive at T2. HD patients who became seropositive following the first dose displayed higher CD19+ B lymphocytes compared to their seronegative HD counterparts. A positive correlation was established between CD19+ B cells counts and antibody titers at all time-points in both groups (p < 0.001). KTRs showed higher naïve CD4+CD45RA+ T helper cells compared to HD patients at baseline and T2 whereas HD patients displayed higher memory CD45RO+ T cells compared to KTRs at T2. The naïve CD4+CD45RA to memory CD4+CD45RO+ T helper cells fraction was negatively associated with antibody production in both groups.ConclusionsOur study provides a potential conceptual framework for monitoring vaccination efficacy in HD patients and KTRs considering the correlation established between CD19+ B cells, generation of memory CD4+ T helper cells and anti SARS-CoV2 antibody response to vaccination.


Sign in / Sign up

Export Citation Format

Share Document